

REMARKS

The dependent claims have all been rewritten and renumbered so as to obviate the objections set forth in the Office Action.

In response to the rejection under 35 U.S.C. § 112, second paragraph, the claims have been amended so as to show the location of the cyclizing bond in the peptide sequence. Nomenclature of this type has previously been employed in U.S. Patent No. 5,663,292 and it is believed that such should be similarly acceptable here. Claim 14 is shown with a dotted cyclizing bond line as it reads upon the products of Example 1 set forth on pages 15-18, in which instance it was found that the linear peptide, as well as the cyclic peptide, showed both potency as an agonist and differential affinity for CRFR1 and CRFR2, as described on page 17, line 18 through page 18, line 7.

With these changes, it is believed that the claims now pending, i.e. claims 13-21, should be acceptable, and allowance thereof is respectfully requested. Hopefully, this paper places the application in condition for allowance, and favorable action is courteously solicited. Should any matter remain unresolved, a telephone call to the undersigned would be appreciated so that prosecution of this application can be completed at an early date.

Dated: July 1, 2008

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Address all correspondence to:
FITCH, EVEN, TABIN & FLANNERY
120 So. LaSalle Street, Ste. 1600
Chicago, IL 60603

/James J. Schumann/
James J. Schumann
Attorney for Applicant(s)
Reg. No. 20,856

Direct telephone inquiries to:
James J. Schumann
(858) 552-1311
San Diego, California Office of
FITCH, EVEN, TABIN & FLANNERY